Literature DB >> 5151306

5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.

B Johansson, B E Roos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5151306     DOI： 10.1007/BF00565012

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  29 in total

1.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM.

Authors:  K FUXE
Journal:  Acta Physiol Scand Suppl       Date:  1965

2.  Are dihydroxphenylalanine decarboxylase and 5-hydroxytrptophan decarboxylase individual enzymes?

Authors:  E ROSENGREN
Journal:  Acta Physiol Scand       Date:  1960-08-25

3.  Effects of antidepressant drugs of the imipramine type on central 5-hydroxytryptamine neurotransmission.

Authors:  J Meek; K Fuxe; N E Andén
Journal:  Eur J Pharmacol       Date:  1970-03       Impact factor: 4.432

Review 4.  Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain.

Authors:  A T Moir; G W Ashcroft; T B Crawford; D Eccleston; H C Guldberg
Journal:  Brain       Date:  1970       Impact factor: 13.501

5.  The effect of L-dopa on monoamine metabolites in Parkinson's disease.

Authors:  M H van Woert; M B Bowers
Journal:  Experientia       Date:  1970

6.  Homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in serial samples of cerebrospinal fluid from the lateral ventricle of the dog.

Authors:  G W Ashcroft; T B Crawford; R C Dow; H C Guldberg
Journal:  Br J Pharmacol Chemother       Date:  1968-07

7.  Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.

Authors:  R Olsson; B E Roos
Journal:  Nature       Date:  1968-08-03       Impact factor: 49.962

8.  Some studies of the effects of chlorpromazine, reserpine and dihydroxyphenylalanine on the concentrations of homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using the technique of serial sampling of the cerebrospinal fluid.

Authors:  H C Guldberg; C M Yates
Journal:  Br J Pharmacol Chemother       Date:  1968-07

9.  Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid.

Authors:  H C Guldberg; G W Ashcroft; T B Crawford
Journal:  Life Sci       Date:  1966-09       Impact factor: 5.037

10.  Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.

Authors:  M H van Woert; M B Bowers
Journal:  Neurology       Date:  1970-04       Impact factor: 9.910
View more
  3 in total

1.  Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors:  G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.

Authors:  C Casati; A Agnoli; A Jori; E Dolfini
Journal:  Z Neurol       Date:  1973-04-02

Review 3.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.